Elysium Therapeutics to Unveil Innovative Solutions at BIO International Convention 2025
Elysium Therapeutics, a pioneering biopharmaceutical firm committed to overcoming the opioid crisis, is gearing up for its participation in the BIO International Convention in Boston, Massachusetts, from June 16 to June 19, 2025. Co-founder and CEO Greg Sturmer is set to highlight the pressing challenge of 'fentanyl rebound,' a phenomenon that complicates opioid overdose situations. This year’s convention will be a crucial platform for discussions surrounding innovative approaches to treating overdose caused by synthetic opioids such as fentanyl.
With the ongoing opioid crisis escalating, the need for effective rescue medications has never been more urgent. Existing treatments, including widely used naloxone, were not designed with synthetic opioids in mind, leaving emergency responders with inadequate tools to combat overdose incidents effectively. Elysium aims to change this narrative with its new Synthetic Opioid Overdose Prevention and Reversal (SOOPR) program. This breakthrough treatment is anticipated to be the first of its kind that offers both rapid onset effects and extended duration of action, designed specifically to tackle the deadly impacts of fentanyl overdoses.
Sturmer remarks, "The critical challenge in addressing the opioid overdose crisis is the mismatch between the increasingly potent illicit opioids available and the current rescue tools that our first responders can employ. Elysium Therapeutics is committed to bridging this gap with our innovative SOOPR technology."
SOOPR combines a long-acting naloxone formulation with advanced delivery technology to offer improvements over standard treatments. This newly formulated agent aims to restore normal respiration quickly while providing up to 24 hours of opioid blockade, significantly reducing the risks associated with re-narcotization. The technology promises to offer much-needed protection from the dangers of opioid misuse while also addressing the pressing needs of users at risk.
During the convention, Greg Sturmer plans to conduct one-on-one meetings with accredited investors and potential partners, aiming to engage in meaningful discussions about the SOOPR initiative and its potential role in reversing the opioid crisis. The expectation is high that these discussions will pave the way for future collaborations that can bring innovative solutions to the market at accelerating speeds.
In addition to SOOPR, Elysium Therapeutics is dedicated to developing other safety-focused options for opioid treatment. Their approach also emphasizes creating safer medications through their SMART (Safer Medicines Alleviate Risks and Trauma) initiative, designed to minimize the risks associated with opioid use while providing effective pain management solutions.
With opioid overdose deaths reaching alarming rates globally, Elysium’s innovative programs such as SOOPR could introduce new standards in overdose management. Their pioneering technologies are developed with insights from healthcare professionals and first responders, ensuring that the solutions are practical and address real-world challenges in treating opioid addiction and overdose.
As Elysium Therapeutics approaches this convention, the spotlight is set on how its contributions might enhance emergency response protocols and ultimately save lives affected by the synthetic opioid crisis. Interested parties can learn more about Elysium Therapeutics by visiting their website at https://www.elysiumrx.com.
With the ongoing opioid crisis escalating, the need for effective rescue medications has never been more urgent. Existing treatments, including widely used naloxone, were not designed with synthetic opioids in mind, leaving emergency responders with inadequate tools to combat overdose incidents effectively. Elysium aims to change this narrative with its new Synthetic Opioid Overdose Prevention and Reversal (SOOPR) program. This breakthrough treatment is anticipated to be the first of its kind that offers both rapid onset effects and extended duration of action, designed specifically to tackle the deadly impacts of fentanyl overdoses.
Sturmer remarks, "The critical challenge in addressing the opioid overdose crisis is the mismatch between the increasingly potent illicit opioids available and the current rescue tools that our first responders can employ. Elysium Therapeutics is committed to bridging this gap with our innovative SOOPR technology."
SOOPR combines a long-acting naloxone formulation with advanced delivery technology to offer improvements over standard treatments. This newly formulated agent aims to restore normal respiration quickly while providing up to 24 hours of opioid blockade, significantly reducing the risks associated with re-narcotization. The technology promises to offer much-needed protection from the dangers of opioid misuse while also addressing the pressing needs of users at risk.
During the convention, Greg Sturmer plans to conduct one-on-one meetings with accredited investors and potential partners, aiming to engage in meaningful discussions about the SOOPR initiative and its potential role in reversing the opioid crisis. The expectation is high that these discussions will pave the way for future collaborations that can bring innovative solutions to the market at accelerating speeds.
In addition to SOOPR, Elysium Therapeutics is dedicated to developing other safety-focused options for opioid treatment. Their approach also emphasizes creating safer medications through their SMART (Safer Medicines Alleviate Risks and Trauma) initiative, designed to minimize the risks associated with opioid use while providing effective pain management solutions.
With opioid overdose deaths reaching alarming rates globally, Elysium’s innovative programs such as SOOPR could introduce new standards in overdose management. Their pioneering technologies are developed with insights from healthcare professionals and first responders, ensuring that the solutions are practical and address real-world challenges in treating opioid addiction and overdose.
As Elysium Therapeutics approaches this convention, the spotlight is set on how its contributions might enhance emergency response protocols and ultimately save lives affected by the synthetic opioid crisis. Interested parties can learn more about Elysium Therapeutics by visiting their website at https://www.elysiumrx.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.